Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.

Blood Adv 2019 03;3(5):797-812

Division of Medical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; and.

The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a variety of cancers, including multiple myeloma (MM). MM is a malignancy of plasma cells that is considered treatable but incurable because of the 90% relapse rate that is primarily from drug resistance. The systemic nature of MM and the antitumor immunosuppression by its tumor microenvironment presents an ongoing therapeutic challenge. In the present study, we demonstrate that RV synergizes with the standard-of-care MM drug bortezomib (BTZ) and, importantly, enhances its therapeutic potential in therapy-resistant human MM cell lines in vitro. Using the syngeneic Vk*MYC BTZ-resistant immunocompetent transplantable MM murine model, we also demonstrate that mice harboring BTZ-insensitive MM tumors respond to the RV/BTZ combination treatment in terms of decreased tumor burden and improved overall survival ( < .00001). We demonstrate that BTZ augments RV replication in tumor-associated endothelial cells and myeloma cells, leading to enhanced viral delivery and thereby stimulating cytokine release, immune activity, apoptosis, and reduction of the MM-associated immune suppression. We conclude that combined RV/BTZ is an attractive therapeutic strategy with no safety signals for the treatment of MM.

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018025593DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418503PMC
March 2019

Publication Analysis

Top Keywords

multiple myeloma
8
importantly enhances
4
enhances therapeutic
4
viral delivery
4
bortezomib btz
4
drug bortezomib
4
therapeutic potential
4
btz importantly
4
enhanced viral
4
cell lines
4
lines vitro
4
cells leading
4
leading enhanced
4
human cell
4
potential therapy-resistant
4
therapy-resistant human
4
standard-of-care drug
4
synergizes standard-of-care
4
tumor microenvironment
4
cytokine release
4

Altmetric Statistics

Similar Publications